Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective faithfully but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my last several shares. The 1st CytoDyn article of mine, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set out the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire employment interview that I came away with a bad opinion of the company.

Irony of irony, the bad viewpoint of mine of the company has grown steadily, however, the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this technology and also connected intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 huge number of) and the very first brand new drug application endorsement ($5 million), and even royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and many therapies, it’s this individual remedy as well as a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

The opening banner of its on the website of its (below) shows an active business with diverse interests albeit focused on leronlimab, multiple illness sorts, multiple delivering presentations and multiple publications.

Can it all be smoke and mirrors? That is a question I’ve been asking myself with the very beginning of my interest in this particular organization. Judging by way of the multiples of thousands of several responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this question.

CytoDyn is a traditional battleground, or perhaps some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *